The National Pharmaceutical Pricing Authority (NPPA) has revised retail prices of 22 formulations under Drugs (Prices Control) Order, 2013 in a notification dated 12 June 2018.
Name of the formulations are methylcobalamin + alpha lipoic acid + pyridoxine hydrochloride+folic acid + vitamin D3 1000IU tablet, cefixime + cloxacillin+lactic acid tablet (ZIFI LBX +200), omeprazole + domperidone capsule (OZSON – DSR), clotrimazole+ beclomethasone cream (CZSON- B), clotrimazole+ beclomethasone+ neomycin cream (CZSON- NB), linezolid suspension (ZIFI TURBO KID), suspension (LIZOFLY), rosuvastatin + clopidogrel tablet (ROSUVAS CV 10), olmesartan + amlodipine + amlodipine tablet (Triolmezest CH 20), olmesartan+ amlodipine + amlodipine tablet (Triolmezest CH 40), telmisartan + amlodipine + chlorthalidone tablet (Telvas 3D CT 40/6.25), telmisartan+ amlodipine+ chlorthalidone tablet (Telvas 3D CT 80/6.25), Alpha lipoic + vitamin D3 + pyridoxine + mecobalamin + folic acid + biotin tablet (Nervijen D3 ) Omega - 3 ( Eicosapentaenoic + Docosahexaenoic) + mecobalamine + pyridoxine + folic acid + vitamin E + vitamin C + zinc sulphate+sodium selenite capsule (Omegaful), thiamine mononitrate + pyridoxine hydrochloride + cyanocobalamin + nicotinamide + calcium pantothenate + riboflavin + vitamin C + folic acid tablet (Sioneuron F), tenofovir disoproxil fumarate + lamividine + efavirenz tablet (AVONZA), diclofenac + methyl salcylate + menthol (Volini Maxx Spray in 55gm pack)
Every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form - III of Schedule - II of the DPCO, 2013 through IPDMS.
Any manufacturer, in respect of discontinuation of production and/or import of scheduled formulation in Form -IV of Schedule - II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
The manufacturers not complying with the ceiling price and notes specified shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
